Search

CytoSorbents Corp

Gesloten

SectorGezondheidszorg

6.32 0.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.31

Max

6.5

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.4M

-9.5M

Verkoop

769K

9.6M

EPS

-0.07

Winstmarge

-99.107

Werknemers

129

EBITDA

547K

-3.3M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-88.3% downside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.1M

Vorige openingsprijs

6

Vorige sluitingsprijs

6.32

Nieuwssentiment

By Acuity

70%

30%

297 / 339 Rangschikking in Healthcare

CytoSorbents Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 sep 2026, 17:46 UTC

News

CytoSorbents Corp shares are declining amid ongoing concerns about regulatory approval processes, despite announcing participation in the H.C. Wainwright conference.

9 sep 2026, 22:16 UTC

Shares of Cytosorbents Corp. traded higher during after-market hours, despite retracing from earlier gains and remaining below its 20-day moving average.

8 sep 2026, 20:01 UTC

Event

Cytosorbents Corp shares are higher following a 1-for-20 reverse stock split, showing strong momentum since Friday's close despite remaining below the 20-day moving average.

4 sep 2026, 23:20 UTC

Event

Cytosorbents Corp shares fell sharply in after-market hours following a reverse stock split of 1 for 20, trading significantly below their 20-day moving average.

3 sep 2026, 20:02 UTC

News

Cytosorbents Corporation shares are lower as the company announced a one-for-twenty reverse stock split to meet Nasdaq's minimum bid price requirement of $1.00.

2 sep 2026, 23:01 UTC

Cytosorbents Corp shares are lower in after-market trading, following significant volatility and amid heightened market sentiment from escalating U.S.-Iran tensions.

1 sep 2026, 20:01 UTC

Cytosorbents Corp shares are lower today, reflecting a modest decline since Monday's close. Broader market concerns may be influencing investor sentiment.

31 aug 2026, 21:01 UTC

Cytosorbents Corp shares are lower in after-market hours, continuing a five-session decline amid broader market pressures from hawkish Fed commentary.

28 aug 2026, 21:01 UTC

Cytosorbents Corp shares are lower in after-market trading after a volatile session, having declined following an initial rise earlier today. No specific news was identified.

27 aug 2026, 19:36 UTC

Cytosorbents Corp shares are lower today, reflecting broader market declines amid inflation data and speculation over potential Federal Reserve interest rate hikes.

26 aug 2026, 19:16 UTC

Cytosorbents Corp shares are higher amid notable volatility during Wednesday's session, fluctuating significantly while remaining in the middle of their one-month trading range.

25 aug 2026, 19:02 UTC

Cytosorbents Corp's shares are lower today, reversing earlier gains amid notable volatility. The stock has declined since Monday's close.

24 aug 2026, 21:01 UTC

Cytosorbents Corp shares are lower in after-market trading amid unusual volatility, despite earlier gains that pushed the stock near its one-month trading range.

21 aug 2026, 20:01 UTC

Cytosorbents Corp shares are higher today, continuing a strong upward trend since Thursday's close amid positive market sentiment and related equity gains.

20 aug 2026, 23:01 UTC

Cytosorbents Corp shares are lower in after-market hours, continuing a decline amid broader market pressure from disappointing sales growth at Walmart Inc.

18 aug 2026, 20:06 UTC

Cytosorbents Corp shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and persistent inflation concerns. No specific news was identified.

17 aug 2026, 19:36 UTC

Cytosorbents Corp shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

14 aug 2026, 20:06 UTC

Cytosorbents Corp shares are higher today, continuing a notable upward trend despite mixed market sentiment and no specific company news identified.

13 aug 2026, 19:16 UTC

Cytosorbents Corp shares are higher today, reflecting routine performance and buoyed by overall market sentiment, despite no specific news driving the movement.

12 aug 2026, 19:46 UTC

Cytosorbents Corp is trading higher, building on gains since Tuesday's close. Broader market sentiment is positive amid favorable inflation data and strong tech earnings.

11 aug 2026, 22:01 UTC

Cytosorbents Corp shares are higher in after-market trading, following notable activity after the market closed, despite no specific company news identified.

10 aug 2026, 19:21 UTC

News

Cytosorbents Corp shares are higher, driven by gains in the Health Care Equipment sector. The company reported Q2 revenue of $9.63 million, exceeding forecasts.

7 aug 2026, 20:51 UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6 aug 2026, 19:16 UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5 aug 2026, 22:06 UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4 aug 2026, 21:01 UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3 aug 2026, 19:56 UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31 jul 2026, 20:06 UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29 jul 2026, 20:08 UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28 jul 2026, 18:46 UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

Peer Vergelijking

Prijswijziging

CytoSorbents Corp Prognose

Koersdoel

By TipRanks

-88.3% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 0.75 USD  -88.3%

Hoogste 0.75 USD

Laagste 0.75 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor CytoSorbents Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

0

Buy

1

Hold

0

Sell

Sentiment

By Acuity

297 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
help-icon Live chat